2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene has been researched along with tetracaine in 1 studies
| Studies (2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene) | Trials (2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene) | Recent Studies (post-2010) (2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene) | Studies (tetracaine) | Trials (tetracaine) | Recent Studies (post-2010) (tetracaine) |
|---|---|---|---|---|---|
| 10 | 0 | 0 | 2,688 | 349 | 274 |
| Protein | Taxonomy | 2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene (IC50) | tetracaine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 3.268 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 0.317 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 3.415 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.268 | |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | 0.056 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.5075 | |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | 1.4693 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 0.795 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.673 | |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | 0.74 | |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | 0.52 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
1 other study(ies) available for 2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene and tetracaine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |